Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 3/20 | 0.57 |
| ▸ | PDE7A | Q13946 | 11/20 | 0.52 |
| ▸ | PDE7B | Q9NP56 | 4/20 | 0.52 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.50 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.43 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.43 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.43 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MERTK | Q12866 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3103805 | 0.94 | VCAM1 (0.51) | VCAM1PDE7APDE7BPDE4BPDE4D | |
| SCHEMBL2018745 | 0.83 | PDE7A (0.62) | VCAM1PDE7APDE7BPDE4BPDE4D | |
| SCHEMBL694430 | 0.81 | VCAM1 (0.62) | VCAM1PDE7APDE7BPDE4BPDE4D | |
| SCHEMBL4255731 | 0.81 | MAPT (0.60) | VCAM1PDE7APDE7BPDE4BPDE4D | |
| SCHEMBL6519015 | 0.79 | VCAM1 (0.62) | VCAM1TXNRD1TXNRD3TXNRD2TDP1 | |
| SCHEMBL695567 | 0.75 | SLC6A2 (0.47) | PDE7AL3MBTL1 | |
| SCHEMBL6463 | 0.74 | VCAM1 (1.00) | VCAM1TDP1MERTK | |
| SCHEMBL12253372 | 0.74 | VCAM1 (1.00) | VCAM1TDP1MERTK | |
| SCHEMBL694090 | 0.73 | TRPV4 (0.44) | VCAM1 | |
| SCHEMBL694367 | 0.73 | VCAM1 (0.48) | VCAM1TXNRD1TXNRD3TXNRD2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2749554-B1 | 2,5-disubstituted arylsulfonamide CCR3 antagonists | SMA THERAPEUTICS INC (US) | 2017-12-20 | — | — | EP | disclosed |
| EP-2749554-B1 | 2,5-disubstituted arylsulfonamide CCR3 antagonists | SMA THERAPEUTICS INC (US) | 2017-12-20 | — | — | EP | disclosed |
| US-20160031841-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. | 2016-02-04 | — | — | US | disclosed |
| US-20160031841-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. | 2016-02-04 | — | — | US | disclosed |
| US-20160031841-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. | 2016-02-04 | — | — | US | disclosed |
| US-9187425-B2 | 2,5-disubstituted arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-9187425-B2 | 2,5-disubstituted arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-9187425-B2 | 2,5-disubstituted arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| CN-102459177-B | The dibasic Arylsulfonamide ccr 3 antagonists of 2,5- | AXIKIN PHARMACEUTICALS, INC. (US) | 2015-09-02 | — | — | CN | disclosed |
| EP-2749554-A2 | 2,5-disubstituted arylsulfonamide CCR3 antagonists | Axikin Pharmaceuticals, Inc. (US) | 2014-07-02 | — | — | EP | disclosed |
| US-8318747-B2 | 2,5-disubstituted arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318747-B2 | 2,5-disubstituted arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318747-B2 | 2,5-disubstituted arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| CN-102459177-A | 2,5-disubstituted arylsulfonamide ccr3 antagonists | AXIKIN PHARMACEUTICALS INC | 2012-05-16 | — | — | CN | disclosed |
| EP-2421830-A2 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | Axikin Pharmaceuticals, Inc. (US) | 2012-02-29 | — | — | EP | disclosed |
| WO-2010123959-A2 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010123959-A2 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2010-10-28 | — | — | WO | disclosed |
| US-20100273785-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. | 2010-10-28 | — | — | US | disclosed |
| US-20100273785-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. | 2010-10-28 | — | — | US | disclosed |
| US-20100273785-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031841-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | CCR3, CCR1, CCR4 | VCAM1 1448/4885PDE7A 2273/4885PDE7B 1301/4885 |
| US-20100273785-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | CCR3, CCR1, CCR4 | VCAM1 2012/4885PDE7A 2839/4885PDE7B 2121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.